Aequus Pharmaceuticals (CVE:AQS) Reaches New 12-Month Low – What’s Next?

Aequus Pharmaceuticals Inc. (CVE:AQS) hit a new 52-week low on Wednesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 4000 shares trading hands. The stock had previously closed at C$0.02.

Aequus Pharmaceuticals Trading Down 33.3 %

The business’s 50 day moving average is C$0.02 and its two-hundred day moving average is C$0.02. The firm has a market capitalization of C$1.33 million, a P/E ratio of -1.00 and a beta of 0.05. The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88.

Aequus Pharmaceuticals (CVE:AQS) last released its quarterly earnings results on Thursday, August 29th. The company reported C($0.01) EPS for the quarter. The business had revenue of C$0.16 million for the quarter. Analysts expect that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current year.

Aequus Pharmaceuticals Company Profile

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.